References

Abrams, J., R. Erwin, G. Fyfe, R. L. Schilsky, and R. Temple. 2009. Data submission standards and evidence requirements. Presented at the Conference on Clinical Cancer Research, Panel 1. Engelberg Center for Health Care Reform, Brookings Institution, Washington, DC.

Abrams, J. S., M. M. Mooney, J. A. Zwiebel, E. L. Korn, S. H. Friedman, S. R. Finnigan, P. R. Schettino, A. M. Denicoff, M. G. Kruhm, M. Montello, R. R. Misra, S. S. Ansher, K. J. Dipiazza, E. M. Souhan, D. L. Wickerham, B. J. Giantonio, R. T. O’Donnell, D. M. Sullivan, N. I. Soto, G. F. Fleming, S. A. Prindiville, R. A. Petryshyn, J. A. Hautala, O. Grad, B. L. Zuckerman, R. M. Meyer, J. C. Yao, L. A. Baker, J. C. Buckner, G. N. Hortobagyi, and J. H. Doroshow. 2013. Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials. Journal of the National Cancer Institute 105(13):947-953.

Amit, O., F. Mannino, A. M. Stone, W. Bushnell, J. Denne, J. Helterbrand, and H. U. Burger. 2011. Blinded independent central review of progression in cancer clinical trials: Results from a meta-analysis. European Journal of Cancer 47(12):1772-1778.

Burstein, H. J. 2011. Bevacizumab for advanced breast cancer: All tied up with a ribbon? Journal of Clinical Oncology 29(10):1232-1235.

Califf, R. M., D. A. Zarin, J. M. Kramer, R. E. Sherman, L. H. Aberle, and A. Tasneem. 2012. Characteristics of clinical trials registered in clinicaltrials.Gov, 2007-2010. Journal of the American Medical Association 307(17):1838-1847.

CFF (Cystic Fibrosis Foundation). 2012. Kalydecohttp://www.cff.org/treatments/therapies/kalydeco (accessed May 9, 2013).



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement



Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 75
References Abrams, J., R. Erwin, G. Fyfe, R. L. Schilsky, and R. Temple. 2009. Data submission standards and evidence requirements. Presented at the Conference on Clinical Cancer Research, Panel 1. Engelberg Center for Health Care Reform, Brookings Institution, Washington, DC. Abrams, J. S., M. M. Mooney, J. A. Zwiebel, E. L. Korn, S. H. Friedman, S. R. Finnigan, P. R. Schettino, A. M. Denicoff, M. G. Kruhm, M. Montello, R. R. Misra, S. S. Ansher, K. J. Dipiazza, E. M. Souhan, D. L. Wickerham, B. J. Giantonio, R. T. O’Donnell, D. M. Sullivan, N. I. Soto, G. F. Fleming, S. A. Prindiville, R. A. Petryshyn, J. A. Hautala, O. Grad, B. L. Zuckerman, R. M. Meyer, J. C. Yao, L. A. Baker, J. C. Buckner, G. N. Hortobagyi, and J. H. Doroshow. 2013. Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials. Journal of the National Cancer Institute 105(13):947-953. Amit, O., F. Mannino, A. M. Stone, W. Bushnell, J. Denne, J. Helterbrand, and H. U. Burger. 2011. Blinded independent central review of progression in cancer clinical trials: Results from a meta-analysis. European Journal of Cancer 47(12):1772-1778. Burstein, H. J. 2011. Bevacizumab for advanced breast cancer: All tied up with a ribbon? Journal of Clinical Oncology 29(10):1232-1235. Califf, R. M., D. A. Zarin, J. M. Kramer, R. E. Sherman, L. H. Aberle, and A. Tasneem. 2012. Characteristics of clinical trials registered in clinicaltrials.Gov, 2007-2010. Journal of the American Medical Association 307(17):1838-1847. CFF (Cystic Fibrosis Foundation). 2012. Kalydeco™. http://www.cff.org/treatments/ therapies/kalydeco (accessed May 9, 2013). 75

OCR for page 75
76 IMPLEMENTING A NATIONAL CANCER CLINICAL TRIALS SYSTEM Cortazar, P., L. Zhang, M. Untch, K. Mehta, J. Costantino, N. Wolmark, H. Bonnefoi, D. Cameron, L. Gianni, P. Valagussa, J. Zujewski, R. Justice, S. Loibl, L. Wickerham, J. Bogaerts, J. Baselga, C. Perou, G. Blumenthal, J. Blohmer, E. Mamounas, J. Bergh, V. Semiglazov, T. Prowell, H. Eidtmann, S. Paik, M. Piccart, R. Sridhara, P. Fasching, S. Swain, L. Slaets, S. Tang, B. Gerber, C. Geyer, R. Pazdur, N. Ditsch, P. Rastogi, W. Eiermann, and G. von Mincwitz. 2012. Meta-analysis results from the collaborative trials in neoadjuvant breast cancer (CTNEOBC). Paper presented at San Antonio Breast Cancer Symposium, San Antonio, TX, December 5. Dodd, L. E., E. L. Korn, B. Freidlin, C. C. Jaffe, L. V. Rubinstein, J. Dancey, and M. M. Mooney. 2008. Blinded independent central review of progression-free survival in phase III clinical trials: Important design element or unnecessary expense? Journal of Clinical Oncology 26(22):3791-3796. Eichler, H. G., K. Oye, L. G. Baird, E. Abadie, J. Brown, C. L. Drum, J. Ferguson, S. Garner, P. Honig, M. Hukkelhoven, J. C. Lim, R. Lim, M. M. Lumpkin, G. Neil, B. O’Rourke, E. Pezalla, D. Shoda, V. Seyfert-Margolis, E. V. Sigal, J. Sobotka, D. Tan, T. F. Unger, and G. Hirsch. 2012. Adaptive licensing: Taking the next step in the evolution of drug approval. Clinical Pharmacology and Therapeutics 91(3):426-437. EMA (European Medicines Agency). 2010. Questions and answers on the review of avastin (bevacizumab) in the treatment of metastatic breast cancer. http://www.ema.europa.eu/ docs/en_GB/document_library/Medicine_QA/2010/12/WC500099939.pdf (accessed May 16, 2013). FDA (Food and Drug Administration). 2006. Information sheet guidance for IRBs, clinical investigators, and sponsors: Significant risk and nonsignificant risk medical device studies. http://www.fda.gov/downloads/regulatoryinformation/guidances/ucm126418.pdf (accessed May 9, 2013). ———. 2012a. Draft guidance for industry and FDA staff. Medical devices: The pre- submission program and meetings with FDA staff. http://www.fda.gov/MedicalDevices/ DeviceRegulationandGuidance/GuidanceDocuments/ucm310375.htm (accessed May 9, 2013). ———. 2012b. FDA briefing document. Oncologic drugs advisory committee meeting. July 24, 2012. Evaluation of radiologic review of progression-free survival in non- hematologic malignancies. http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/ UCM311141.pdf (accessed May 9, 2013). ———. 2012c. Guidance for industry on determining the extent of safety data collection needed in late stage premarket and postapproval clinical investigations. https://s3.amazonaws.com/ public-inspection.federalregister.gov/2012-03096.pdf (accessed May 9, 2013). ———. 2012d. Guidance for IRBs, clinical investigators and sponsors: IRB responsibilities for reviewing the qualifications of investigators, adequacy of research sites, and the determination of whether an IND/IDE is needed. http://www.fda.gov/RegulatoryInformation/ Guidances/ucm366335.htm (accessed May 9, 2013). ———. 2012e. Kalydeco (ivacaftor) information. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm323671.htm (accessed May 9, 2013). Freidlin, B., L. M. McShane, and E. L. Korn. 2010. Randomized clinical trials with biomarkers: Design issues. Journal of the National Cancer Institute 102(3):152-160.

OCR for page 75
REFERENCES 77 Hamburg, M. 2010. Drug regulation in the modern era. 11th Annual HBS Industry Alumni Association Conference. November 5, 2010, Boston, MA. Hirsch, B. R., R. M. Califf, S. K. Cheng, A. Tasneem, J. Horton, K. Chiswell, K. A. Schulman, D. M. Dilts, and A. P. Abernethy. 2013. Characteristics of oncology clinical trials: Insights from a systematic analysis of ClinicalTrials.gov. JAMA Internal Medicine 173(11):972-979. IOM (Institute of Medicine). 2010a. A foundation for evidence-driven practice: A rapid learning system for cancer care: Workshop summary. Washington, DC: The National Academies Press. ———. 2010b. A national cancer clinical trials system for the 21st century: Reinvigorating the NCI cooperative group program. Washington, DC: The National Academies Press. ———. 2011. Implementing a national cancer clinical trials system for the 21st century: Workshop summary. Washington, DC: The National Academies Press. Kaiser, J. 2013. Rare cancer successes spawn “exceptional” research efforts. Science 340(6130):263. Kaitin, K. I., and J. A. DiMasi. 2011. Pharmaceutical innovation in the 21st century: New drug approvals in the first decade, 2000-2009. Clinical Pharmacology and Therapeutics 89(2):183-188. National Human Genome Research Institute. 2013. Clinical Sequencing Exploratory Research (CSER). http://www.genome.gov/27546194 (accessed May 30, 2013). NCI (National Cancer Institute). 2012. NCI Office of Cancer Centers (OCC) learning series. An overview of the NCI’s Community Oncology Research Program. http://cancercenters. cancer.gov/Webinar/NCORP/NCORPwebinar.html (accessed May 9, 2013). NCI and CEO Roundtable on Cancer. 2008. Proposed standardized/harmonized clauses for clinical trial agreement. http://transformingtrials.cancer.gov/files/StClauses.pdf (accessed May 9, 2013). Stephens, P. J., P. S. Tarpey, H. Davies, P. Van Loo, C. Greenman, D. C. Wedge, S. Nik- Zainal, S. Martin, I. Varela, G. R. Bignell, L. R. Yates, E. Papaemmanuil, D. Beare, A. Butler, A. Cheverton, J. Gamble, J. Hinton, M. Jia, A. Jayakumar, D. Jones, C. Latimer, K. W. Lau, S. McLaren, D. J. McBride, A. Menzies, L. Mudie, K. Raine, R. Rad, M. S. Chapman, J. Teague, D. Easton, A. Langerod, M. T. Lee, C. Y. Shen, B. T. Tee, B. W. Huimin, A. Broeks, A. C. Vargas, G. Turashvili, J. Martens, A. Fatima, P. Miron, S. F. Chin, G. Thomas, S. Boyault, O. Mariani, S. R. Lakhani, M. van de Vijver, L. van’t Veer, J. Foekens, C. Desmedt, C. Sotiriou, A. Tutt, C. Caldas, J. S. Reis-Filho, S. A. Aparicio, A. V. Salomon, A. L. Borresen-Dale, A. L. Richardson, P. J. Campbell, P. A. Futreal, and M. R. Stratton. 2012. The landscape of cancer genes and mutational processes in breast cancer. Nature 486(7403):400-404. Trotta, F., H. G. Leufkens, J. H. Schellens, R. Laing, and G. Tafuri. 2011. Evaluation of oncology drugs at the European Medicines Agency and U.S. Food and Drug Administration: When differences have an impact on clinical practice. Journal of Clinical Oncology 29(16):2266-2272. Yelensky, R., G. M. Frampton, A. Fichtenholtz, S. Downing, J. He, F. Juhn, K. Brennan, K. Wang, G. Otto, M. Jarosz, A. Parker, J. S. Ross, J. Curran, M. T. Cronin, P. J. Stephens, and D. Lipson. 2013. Bringing next generation sequencing (NGS) to the clinic: Analytical validation of a comprehensive NGS-based cancer gene test. Paper presented at AACR Annual Meeting 2013, Washington, DC, April 8.

OCR for page 75
78 IMPLEMENTING A NATIONAL CANCER CLINICAL TRIALS SYSTEM Zhang, J. J., H. Chen, K. He, S. Tang, R. Justice, P. Keegan, R. Pazdur, and R. Sridhara. 2013. Evaluation of blinded independent central review of tumor progression in oncology clinical trials: A meta-analysis. Therapeutic Innovation and Regulatory Science 47(2):167-174.